Nasus Pharma (NSRX) vs Telomir Pharmaceuticals (TELO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Nasus Pharma (NSRX) has outperformed Telomir Pharmaceuticals (TELO) over the past year, losing 68.4% versus a loss of 71.6%. Nasus Pharma is the larger company by market cap ($26.8 million vs $26.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NSRX | TELO |
|---|---|---|
| Share price | $2.29 | $0.364 |
| Market cap | $26.82M | $26.82M |
| 1-day change | -10.20% | -17.24% |
| YTD return | -74.97% | -72.63% |
| 1-year return | -68.41% | -71.56% |
| EPS (TTM) | $-1.20 | $-0.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.24B | — |
| Net income (latest FY) | $-5.86M | $-10.41M |
| Operating margin | -0.40% | — |
| Net margin | -0.47% | — |
| 52-week high | $9.50 | $1.58 |
| 52-week low | $1.98 | $0.353 |
| Distance from 52-week high | -75.89% | -76.96% |
| Analyst consensus | buy | none |
| Avg. price target upside | +758.95% | +998.90% |
| Average volume | 16.80K | 126.14K |
| Shares outstanding | 11.71M | 73.68M |
| Employees | 7 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Nasus Pharma
NSRX stock →Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Telomir Pharmaceuticals
TELO stock →Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria.
Health Care · Biotechnology: Pharmaceutical Preparations
NSRX vs TELO FAQ
Which is bigger, Nasus Pharma or Telomir Pharmaceuticals?
Nasus Pharma (NSRX) is larger, with a market capitalization of $26.82M compared with $26.82M for Telomir Pharmaceuticals (TELO).
Which stock has performed better over the past year, NSRX or TELO?
NSRX returned -68.41% over the past 12 months, compared with -71.56% for TELO (price return, excluding dividends). Past performance does not predict future results.
Are Nasus Pharma and Telomir Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.